Vetr Inc. disclosed Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), hiking its price target to $107.00 earlier today
- Updated: September 29, 2016
Having a price of $120.06, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded -2.99% lower on the day. With the last close down -11.19% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. ALXN has recorded a 50-day moving average of $129.48 and a 200-day moving average of $135.19. 1,976,442 shares of ALXN traded hands, up from an average trading volume of 1,571,150
Reporting a potential downside of -0.11%, Vetr Inc. upped the price target of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to $107.00
Recent Performance Chart
Alexion Pharmaceuticals, Inc. has 52 week low of $110.56 and a 52 week high of $193.45 with a PE ratio of 301.66 and has a market capitalization of $0.
A total of 18 brokerages have issued a ratings update on Alexion Pharmaceuticals, Inc.. Seven brokerages rating the company a strong buy, six firms rating the stock a buy, 7 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 equity analysts rating the company a sell with a one year target of $187.61.
More About Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.